Thomas N. Chase, M.D. - Publications

National Institutes of Health, Bethesda, MD 
Parkinson's disease

108 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2008 Vanover KE, Betz AJ, Weber SM, Bibbiani F, Kielaite A, Weiner DM, Davis RE, Chase TN, Salamone JD. A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model. Pharmacology, Biochemistry, and Behavior. 90: 540-4. PMID 18534670 DOI: 10.1016/J.Pbb.2008.04.010  0.388
2007 Liang ZQ, Wang X, Li LY, Wang Y, Chen RW, Chuang DM, Chase TN, Qin ZH. Nuclear factor-kappaB-dependent cyclin D1 induction and DNA replication associated with N-methyl-D-aspartate receptor-mediated apoptosis in rat striatum. Journal of Neuroscience Research. 85: 1295-309. PMID 17385714 DOI: 10.1002/Jnr.21248  0.316
2007 Smith CP, Oh JD, Bibbiani F, Collins MA, Avila I, Chase TN. Tamoxifen effect on L-DOPA induced response complications in parkinsonian rats and primates. Neuropharmacology. 52: 515-26. PMID 17116309 DOI: 10.1016/J.Neuropharm.2006.08.018  0.639
2006 Bara-Jimenez W, Dimitrova TD, Sherzai A, Aksu M, Chase TN. Glutamate release inhibition ineffective in levodopa-induced motor complications. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 1380-3. PMID 16758479 DOI: 10.1002/Mds.20976  0.399
2005 Bibbiani F, Oh JD, Kielaite A, Collins MA, Smith C, Chase TN. Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. Experimental Neurology. 196: 422-9. PMID 16203001 DOI: 10.1016/J.Expneurol.2005.08.017  0.673
2005 Bara-Jimenez W, Bibbiani F, Morris MJ, Dimitrova T, Sherzai A, Mouradian MM, Chase TN. Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 20: 932-6. PMID 15791634 DOI: 10.1002/Mds.20370  0.444
2004 Bara-Jimenez W, Dimitrova T, Sherzai A, Favit A, Mouradian MM, Chase TN. Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 19: 1183-6. PMID 15390018 DOI: 10.1002/Mds.20124  0.407
2004 Wessell RH, Ahmed SM, Menniti FS, Dunbar GL, Chase TN, Oh JD. NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats. Neuropharmacology. 47: 184-94. PMID 15223297 DOI: 10.1016/J.Neuropharm.2004.03.011  0.685
2004 Chase TN. Striatal plasticity and extrapyramidal motor dysfunction. Parkinsonism & Related Disorders. 10: 305-13. PMID 15196510 DOI: 10.1016/j.parkreldis.2004.02.012  0.329
2004 Duan Y, Lipkovich I, Ahmed S, Ahl J, Hardy T, Haldane D, Baker R, Tohen M, Liu-Seifert H, Healey K, Kinon BJ, Ahmed S, Lipkovich IA, Tohen MF, Hoffmann V, ... ... Chase T, ... ... Chase TN, et al. Abstracts from ASENT 2004 Annual Meeting March 11–13, 2004 Neurorx. 1: 506-514. DOI: 10.1602/Neurorx.1.4.506  0.549
2003 Bibbiani F, Oh JD, Petzer JP, Castagnoli N, Chen JF, Schwarzschild MA, Chase TN. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Experimental Neurology. 184: 285-94. PMID 14637099 DOI: 10.1016/S0014-4886(03)00250-4  0.675
2003 Chase TN, Bibbiani F, Oh JD. Striatal glutamatergic mechanisms and extrapyramidal movement disorders. Neurotoxicity Research. 5: 139-46. PMID 12832228 DOI: 10.1007/Bf03033378  0.681
2003 Blanchet PJ, Konitsiotis S, Mochizuki H, Pluta R, Emerich DF, Chase TN, Mouradian MM. Complications of a trophic xenotransplant approach in parkinsonian monkeys. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 27: 607-12. PMID 12787846 DOI: 10.1016/S0278-5846(03)00048-4  0.312
2003 Oh JD, Chartisathian K, Ahmed SM, Chase TN. Cyclic AMP responsive element binding protein phosphorylation and persistent expression of levodopa-induced response alterations in unilateral nigrostriatal 6-OHDA lesioned rats. Journal of Neuroscience Research. 72: 768-80. PMID 12774317 DOI: 10.1002/Jnr.10629  0.669
2003 Oh JD, Geller AI, Zhang Gr, Chase TN. Gene transfer of constitutively active protein kinase C into striatal neurons accelerates onset of levodopa-induced motor response alterations in parkinsonian rats. Brain Research. 971: 18-30. PMID 12691833 DOI: 10.1016/S0006-8993(03)02348-5  0.651
2003 Schwarzschild MA, Chen JF, Chase TN. A2A antagonists for PD: A prime example of translational neuroscience Neurology. 61: S3-S4. DOI: 10.1212/01.Wnl.0000095202.94814.0F  0.368
2002 Oh JD, Bibbiani F, Chase TN. Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models. Experimental Neurology. 177: 557-64. PMID 12429201 DOI: 10.1006/Exnr.2002.8009  0.689
2002 Tessitore A, Hariri AR, Fera F, Smith WG, Chase TN, Hyde TM, Weinberger DR, Mattay VS. Dopamine modulates the response of the human amygdala: a study in Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 22: 9099-103. PMID 12388617 DOI: 10.1523/Jneurosci.22-20-09099.2002  0.337
2002 Oh JD, Chase TN. Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease. Amino Acids. 23: 133-9. PMID 12373527 DOI: 10.1007/s00726-001-0118-2  0.663
2002 Verhagen Metman L, Morris MJ, Farmer C, Gillespie M, Mosby K, Wuu J, Chase TN. Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology. 59: 694-9. PMID 12221159  0.322
2002 Jeffries KJ, Schooler C, Schoenbach C, Herscovitch P, Chase TN, Braun AR. The functional neuroanatomy of Tourette's syndrome: an FDG PET study III: functional coupling of regional cerebral metabolic rates. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 27: 92-104. PMID 12062910 DOI: 10.1016/S0893-133X(01)00428-6  0.321
2002 Mattay VS, Tessitore A, Callicott JH, Bertolino A, Goldberg TE, Chase TN, Hyde TM, Weinberger DR. Dopaminergic modulation of cortical function in patients with Parkinson's disease. Annals of Neurology. 51: 156-64. PMID 11835371 DOI: 10.1002/Ana.10078  0.36
2001 Bibbiani F, Oh JD, Chase TN. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology. 57: 1829-34. PMID 11723272 DOI: 10.1212/Wnl.57.10.1829  0.651
2001 Chase TN, Konitsiotis S, Oh JD. Striatal molecular mechanisms and motor dysfunction in Parkinson's disease. Advances in Neurology. 86: 355-60. PMID 11553996  0.61
2001 Del Dotto P, Pavese N, Gambaccini G, Bernardini S, Metman LV, Chase TN, Bonuccelli U. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Movement Disorders : Official Journal of the Movement Disorder Society. 16: 515-20. PMID 11391748 DOI: 10.1002/Mds.1112  0.428
2001 Hutton JT, Metman LV, Chase TN, Juncos JL, Koller WC, Pahwa R, LeWitt PA, Samii A, Tsui JK, Calne DB, Waters CH, Calabrese VP, Bennett JP, Barrett R, Morris JL. Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study. Movement Disorders : Official Journal of the Movement Disorder Society. 16: 459-63. PMID 11391739 DOI: 10.1002/Mds.1085  0.318
2000 Chase TN, Oh JD. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends in Neurosciences. 23: S86-91. PMID 11052225 DOI: 10.1016/S1471-1931(00)00018-5  0.641
2000 Chase TN, Oh JD, Konitsiotis S. Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. Journal of Neurology. 247: II36-42. PMID 10991664 DOI: 10.1007/Pl00007759  0.66
2000 Konitsiotis S, Blanchet PJ, Verhagen L, Lamers E, Chase TN. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology. 54: 1589-95. PMID 10762498 DOI: 10.1212/Wnl.54.8.1589  0.429
2000 Chase TN, Oh JD. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Annals of Neurology. 47: S122-9; discussion S. PMID 10762139  0.669
2000 Oh JD, Chartisathian K, Chase TN, Butcher LL. Overexpression of neurotrophin receptor p75 contributes to the excitotoxin-induced cholinergic neuronal death in rat basal forebrain. Brain Research. 853: 174-85. PMID 10640615 DOI: 10.1016/S0006-8993(99)02054-5  0.591
2000 Metman LV, Konitsiotis S, Chase TN. Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what. Movement Disorders : Official Journal of the Movement Disorder Society. 15: 3-8. PMID 10634235 DOI: 10.1002/1531-8257(200001)15:1<3::Aid-Mds1003>3.0.Co;2-E  0.376
1999 Agid Y, Ahlskog E, Albanese A, Calne D, Chase T, De Yebenes J, Factor S, Fahn S, Gershanik O, Goetz C, Koller W, Kurth M, Lang A, Lees A, Lewitt P, et al. Levodopa in the treatment of Parkinson's disease: a consensus meeting. Movement Disorders : Official Journal of the Movement Disorder Society. 14: 911-3. PMID 10584663 DOI: 10.1002/1531-8257(199911)14:6<911::Aid-Mds1001>3.0.Co;2-H  0.366
1999 Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Archives of Neurology. 56: 1383-6. PMID 10555659 DOI: 10.1001/Archneur.56.11.1383  0.369
1999 Oh JD, Vaughan CL, Chase TN. Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits. Brain Research. 821: 433-42. PMID 10064831 DOI: 10.1016/S0006-8993(99)01121-X  0.646
1999 Oh JD, Russell DS, Vaughan CL, Chase TN. Corrigendum to: Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and L-DOPA administration Brain Research. 820: 117. PMID 10023039 DOI: 10.1016/S0006-8993(99)01053-7  0.614
1999 Qin Z, Chen R, Wang Y, Nakai M, Chuang D, Chase TN. Nuclear Factor κB Nuclear Translocation Upregulates c-Myc and p53 Expression during NMDA Receptor-Mediated Apoptosis in Rat Striatum The Journal of Neuroscience. 19: 4023-4033. DOI: 10.1523/Jneurosci.19-10-04023.1999  0.301
1998 Verhagen Metman L, Del Dotto P, Blanchet PJ, van den Munckhof P, Chase TN. Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Amino Acids. 14: 75-82. PMID 9871445 DOI: 10.1007/BF01345246  0.309
1998 Blanchet PJ, Fang J, Gillespie M, Sabounjian L, Locke KW, Gammans R, Mouradian MM, Chase TN. Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease. Clinical Neuropharmacology. 21: 339-43. PMID 9844789  0.303
1998 Oh JD, Russell DS, Vaughan CL, Chase TN, Russell D. Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and L-DOPA administration. Brain Research. 813: 150-9. PMID 9824689 DOI: 10.1016/S0006-8993(98)01049-X  0.64
1998 Blanchet PJ, Konitsiotis S, Hyland K, Arnold LA, Pettigrew KD, Chase TN. Chronic exposure to MPTP as a primate model of progressive parkinsonism: a pilot study with a free radical scavenger. Experimental Neurology. 153: 214-22. PMID 9784281 DOI: 10.1006/Exnr.1998.6906  0.366
1998 Fahn S, Clarence-Smith KE, Chase TN. Parkinson's disease: neurodegenerative mechanisms and neuroprotective interventions--report of a workshop. Movement Disorders : Official Journal of the Movement Disorder Society. 13: 759-67. PMID 9756143 DOI: 10.1002/Mds.870130502  0.301
1998 Chase TN, Oh JD, Blanchet PJ. Neostriatal mechanisms in Parkinson's disease. Neurology. 51: S30-5. PMID 9711978 DOI: 10.1212/Wnl.51.2_Suppl_2.S30  0.685
1998 Verhagen Metman L, Blanchet PJ, van den Munckhof P, Del Dotto P, Natté R, Chase TN. A trial of dextromethorphan in parkinsonian patients with motor response complications. Movement Disorders : Official Journal of the Movement Disorder Society. 13: 414-7. PMID 9613730 DOI: 10.1002/Mds.870130307  0.407
1998 Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology. 50: 1323-6. PMID 9595981  0.313
1997 Oh JD, Del Dotto P, Chase TN. Protein kinase A inhibitor attenuates levodopa-induced motor response alterations in the hemi-parkinsonian rat. Neuroscience Letters. 228: 5-8. PMID 9197274 DOI: 10.1016/S0304-3940(97)00355-8  0.676
1997 Blanchet PJ, Papa SM, Metman LV, Mouradian MM, Chase TN. Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease. Neuroscience and Biobehavioral Reviews. 21: 447-53. PMID 9195602 DOI: 10.1016/S0149-7634(96)00038-3  0.339
1997 Mouradian MM, Chase TN. Gene therapy for Parkinson's disease: an approach to the prevention or palliation of levodopa-associated motor complications. Experimental Neurology. 144: 51-7. PMID 9126152 DOI: 10.1006/Exnr.1996.6388  0.431
1996 Marin C, Papa S, Engber TM, Bonastre M, Tolosa E, Chase TN. MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Research. 736: 202-5. PMID 8930325 DOI: 10.1016/0006-8993(96)00693-2  0.339
1996 Blesa R, Mohr E, Miletich RS, Hildebrand K, Sampson M, Chase TN. Cerebral metabolic changes in Alzheimer's disease: neurobehavioral patterns. Dementia (Basel, Switzerland). 7: 239-45. PMID 8872413 DOI: 10.1159/000106886  0.307
1996 Metman LV, Blanchet PJ, de Jong D, Mouradian MM, Chase TN. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 11: 257-60. PMID 8723141 DOI: 10.1002/mds.870110307  0.304
1996 Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Annals of Neurology. 39: 574-8. PMID 8619541 DOI: 10.1002/Ana.410390505  0.419
1995 Papa SM, Boldry RC, Engber TM, Kask AM, Chase TN. Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Research. 701: 13-8. PMID 8925275 DOI: 10.1016/0006-8993(95)00924-3  0.365
1995 Boldry RC, Papa SM, Kask AM, Chase TN. MK-801 reverses effects of chronic levodopa on D1 and D2 dopamine agonist-induced rotational behavior. Brain Research. 692: 259-64. PMID 8548312 DOI: 10.1016/0006-8993(95)00690-R  0.379
1995 Chase TN, Metman LV, Bravi D, Roberts JW, Sibley DR, Mouradian MM. Dopamine-receptor subtype-selective agonists in the treatment of Parkinson's disease Clinical Neuropharmacology. 18: S207-S215. DOI: 10.1097/00002826-199501001-00022  0.394
1994 Blin J, Ray CA, Piercey MF, Bartko JJ, Mouradian MM, Chase TN. Comparison of cholinergic drug effects on regional brain glucose consumption in rats and humans by means of autoradiography and position emission tomography. Brain Research. 635: 196-202. PMID 8173955 DOI: 10.1016/0006-8993(94)91439-7  0.312
1994 Bravi D, Mouradian MM, Roberts JW, Davis TL, Sohn YH, Chase TN. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Annals of Neurology. 36: 27-31. PMID 8024257 DOI: 10.1002/ana.410360108  0.326
1994 Oyanagi K, Makifuchi T, Ohtoh T, Chen KM, Gajdusek DC, Chase TN, Ikuta F. The neostriatum and nucleus accumbens in parkinsonism-dementia complex of Guam: a pathological comparison with Alzheimer's disease and progressive supranuclear palsy. Acta Neuropathologica. 88: 122-8. PMID 7985492 DOI: 10.1007/Bf00294504  0.323
1994 Papa SM, Engber TM, Kask AM, Chase TN. Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Research. 662: 69-74. PMID 7859092 DOI: 10.1016/0006-8993(94)90796-X  0.303
1994 Anderson JJ, Kuo S, Chase TN. Endogenous excitatory amino acids tonically stimulate striatal acetylcholine release through NMDA but not AMPA receptors. Neuroscience Letters. 176: 264-8. PMID 7830961 DOI: 10.1016/0304-3940(94)90097-3  0.339
1994 Engber TM, Papa SM, Boldry RC, Chase TN. NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport. 5: 2586-8. PMID 7696610  0.326
1993 Braun AR, Stoetter B, Randolph C, Hsiao JK, Vladar K, Gernert J, Carson RE, Herscovitch P, Chase TN. The functional neuroanatomy of Tourette's syndrome: an FDG-PET study. I. Regional changes in cerebral glucose metabolism differentiating patients and controls. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 9: 277-91. PMID 8305128 DOI: 10.1038/Npp.1993.64  0.306
1993 Chase TN, Mouradian MM, Engber TM. Motor response complications and the function of striatal efferent systems. Neurology. 43: S23-7. PMID 8264907  0.312
1993 Bravi D, Davis TL, Mouradian MM, Chase TN. Treatment of Parkinson's disease with the partial dopamine agonist EMD 49980. Movement Disorders : Official Journal of the Movement Disorder Society. 8: 195-7. PMID 8097280 DOI: 10.1002/Mds.870080214  0.393
1993 Anderson JJ, Chase TN, Engber TM. Substance P increases release of acetylcholine in the dorsal striatum of freely moving rats. Brain Research. 623: 189-94. PMID 7693302 DOI: 10.1016/0006-8993(93)91426-S  0.326
1992 Baronti F, Davis TL, Boldry RC, Mouradian MM, Chase TN. Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging. Neurology. 42: 541-4. PMID 1549214 DOI: 10.1212/Wnl.42.3.541  0.334
1992 Baronti F, Mouradian MM, Davis TL, Giuffra M, Brughitta G, Conant KE, Chase TN. Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease. Annals of Neurology. 32: 776-81. PMID 1471868 DOI: 10.1002/Ana.410320611  0.422
1992 Anderson JJ, Chase TN, Engber TM. Differential effect of subthalamic nucleus ablation on dopamine D1 and D2 agonist-induced rotation in 6-hydroxydopamine-lesioned rats. Brain Research. 588: 307-10. PMID 1356592 DOI: 10.1016/0006-8993(92)91591-2  0.339
1992 Baronti F, Mouradian MM, Conant KE, Giuffra M, Brughitta G, Chase TN. Partial dopamine agonist therapy of levodopa-induced dyskinesias. Neurology. 42: 1241-3. PMID 1351273 DOI: 10.1212/Wnl.42.6.1241  0.379
1992 Giuffra ME, Mouradian MM, Chase TN. Glutamatergic therapy of Huntington's chorea. Clinical Neuropharmacology. 15: 148-51. PMID 1350513 DOI: 10.1097/00002826-199204000-00009  0.385
1991 Mouradian MM, Blin J, Giuffra M, Heuser IJ, Baronti F, Ownby J, Chase TN. Somatostatin replacement therapy for Alzheimer dementia. Annals of Neurology. 30: 610-3. PMID 1789687 DOI: 10.1002/Ana.410300415  0.314
1991 Baronti F, Conant KE, Giuffra M, Davis TL, Brughitta G, Iadarola MJ, Berrettini WH, Chase TN, Mouradian MM. Opioid peptides in Parkinson's disease: effects of dopamine repletion. Brain Research. 560: 92-6. PMID 1684735 DOI: 10.1016/0006-8993(91)91219-Q  0.397
1990 Mouradian MM, Heuser IJ, Baronti F, Chase TN. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Annals of Neurology. 27: 18-23. PMID 2301923 DOI: 10.1002/Ana.410270105  0.409
1990 Mohr E, Litvan I, Williams J, Fedio P, Chase TN. Selective deficits in Alzheimer and parkinsonian dementia: visuospatial function. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 17: 292-7. PMID 2207883 DOI: 10.1017/S0317167100030596  0.303
1990 Weick BG, Engber TM, Susel Z, Chase TN, Walters JR. Responses of substantia nigra pars reticulata neurons to GABA and SKF 38393 in 6-hydroxydopamine-lesioned rats are differentially affected by continuous and intermittent levodopa administration. Brain Research. 523: 16-22. PMID 2119854 DOI: 10.1016/0006-8993(90)91631-P  0.399
1989 Litvan I, Gomez C, Atack JR, Gillespie M, Kask AM, Mouradian MM, Chase TN. Physostigmine treatment of progressive supranuclear palsy. Annals of Neurology. 26: 404-7. PMID 2802540 DOI: 10.1002/Ana.410260318  0.301
1989 Mouradian MM, Heuser IJ, Baronti F, Fabbrini G, Juncos JL, Chase TN. Pathogenesis of dyskinesias in Parkinson's disease. Annals of Neurology. 25: 523-6. PMID 2774496 DOI: 10.1002/ana.410250521  0.304
1989 Juncos JL, Engber TM, Raisman R, Susel Z, Thibaut F, Ploska A, Agid Y, Chase TN. Continuous and intermittent levodopa differentially affect basal ganglia function. Annals of Neurology. 25: 473-8. PMID 2774488 DOI: 10.1002/ana.410250509  0.333
1989 Chase TN, Baronti F, Fabbrini G, Heuser IJ, Juncos JL, Mouradian MM. Rationale for continuous dopaminomimetic therapy of Parkinson's disease. Neurology. 39: 7-10; discussion 19. PMID 2685653  0.313
1989 Mohr E, Schlegel J, Fabbrini G, Williams J, Mouradian MM, Mann UM, Claus JJ, Fedio P, Chase TN. Clonidine treatment of Alzheimer's disease. Archives of Neurology. 46: 376-8. PMID 2650662 DOI: 10.1001/Archneur.1989.00520400030015  0.346
1989 Mohr E, Fabbrini G, Williams J, Schlegel J, Cox C, Fedio P, Chase TN. Dopamine and memory function in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 4: 113-20. PMID 2543918 DOI: 10.1002/Mds.870040202  0.343
1988 Braun AR, Chase TN. Behavioral effects of chronic exposure to selective D-1 and D-2 dopamine receptor agonists. European Journal of Pharmacology. 147: 441-51. PMID 3259931 DOI: 10.1016/0014-2999(88)90179-3  0.359
1987 Mohr E, Fabbrini G, Ruggieri S, Fedio P, Chase TN. Cognitive concomitants of dopamine system stimulation in parkinsonian patients. Journal of Neurology, Neurosurgery, and Psychiatry. 50: 1192-6. PMID 3668568 DOI: 10.1136/Jnnp.50.9.1192  0.343
1987 Tamminga CA, Tanimoto K, Kuo S, Beck M, Chase TN. Central cholecystokinin octapeptide reduces glucose utilization in subcortical but not cortical rat brain. European Journal of Pharmacology. 139: 237-41. PMID 3653246 DOI: 10.1016/0014-2999(87)90257-3  0.305
1987 Tanimoto K, Tamminga CA, Chase TN. Elevation of plasma prolactin concentrations by intravenous SCH 23390 and SKF 38393 in conscious rats. European Journal of Pharmacology. 144: 147-51. PMID 3325296 DOI: 10.1016/0014-2999(87)90513-9  0.355
1987 Tanimoto K, Tamminga CA, Chase TN, Nilaver G. Intracerebroventricular injection of cholecystokinin octapeptide elevates plasma prolactin levels through stimulation of vasoactive intestinal polypeptide. Endocrinology. 121: 127-32. PMID 3297634 DOI: 10.1210/Endo-121-1-127  0.307
1987 Walters JR, Bergstrom DA, Carlson JH, Chase TN, Braun AR. D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects. Science (New York, N.Y.). 236: 719-22. PMID 2953072 DOI: 10.1126/Science.2953072  0.385
1987 Tamminga CA, Tanimoto K, Kuo S, Chase TN, Contreras PC, Rice KC, Jackson AE, O'Donohue TL. PCP-induced alterations in cerebral glucose utilization in rat brain: blockade by metaphit, a PCP-receptor-acylating agent. Synapse (New York, N.Y.). 1: 497-504. PMID 2850626 DOI: 10.1002/Syn.890010514  0.341
1986 Foster NL, Tamminga CA, O'Donohue TL, Tanimoto K, Bird ED, Chase TN. Brain choline acetyltransferase activity and neuropeptide Y concentrations in Alzheimer's disease. Neuroscience Letters. 63: 71-5. PMID 3754039 DOI: 10.1016/0304-3940(86)90015-7  0.319
1986 Bruno G, Mohr E, Gillespie M, Fedio P, Chase TN. Muscarinic agonist therapy of Alzheimer's disease. A clinical trial of RS-86. Archives of Neurology. 43: 659-61. PMID 3524514 DOI: 10.1001/Archneur.1986.00520070017009  0.353
1986 Braun AR, Chase TN. Obligatory D-1/D-2 receptor interaction in the generation of dopamine agonist related behaviors. European Journal of Pharmacology. 131: 301-6. PMID 3493161 DOI: 10.1016/0014-2999(86)90588-1  0.335
1986 Tamminga CA, Littman RL, Alphs LD, Chase TN, Thaker GK, Wagman AM. Neuronal cholecystokinin and schizophrenia: pathogenic and therapeutic studies. Psychopharmacology. 88: 387-91. PMID 3083460 DOI: 10.1007/Bf00180843  0.309
1986 Braun AR, Barone P, Chase TN. Interaction of D1 and D2 dopamine receptors in the expression of dopamine agonist induced behaviors. Advances in Experimental Medicine and Biology. 204: 151-66. PMID 2947426 DOI: 10.1007/978-1-4684-5191-7_10  0.368
1986 Dawson TM, Barone P, Sidhu A, Wamsley JK, Chase TN. Quantitative autoradiographic localization of D-1 dopamine receptors in the rat brain: use of the iodinated ligand [125I]SCH 23982. Neuroscience Letters. 68: 261-6. PMID 2944035 DOI: 10.1016/0304-3940(86)90499-4  0.353
1986 Ludwig CL, Weinberger DR, Bruno G, Gillespie M, Bakker K, LeWitt PA, Chase TN. Buspirone, Parkinson's disease, and the locus ceruleus. Clinical Neuropharmacology. 9: 373-8. PMID 2873889 DOI: 10.1097/00002826-198608000-00004  0.355
1986 Barone P, Davis TA, Braun AR, Chase TN. Dopaminergic mechanisms and motor function: characterization of D-1 and D-2 dopamine receptor interactions. European Journal of Pharmacology. 123: 109-14. PMID 2872071 DOI: 10.1016/0014-2999(86)90694-1  0.4
1985 Cohen SL, Knight M, Tamminga CA, Chase TN. A comparison of peripheral and central effects of CCK8 on water-reinforced operant responding. European Journal of Pharmacology. 116: 229-38. PMID 4076337 DOI: 10.1016/0014-2999(85)90157-8  0.304
1985 Newman RP, LeWitt PA, Shults C, Bruno G, Foster NL, Chase TN, Calne DB. Dystonia: treatment with bromocriptine. Clinical Neuropharmacology. 8: 328-33. PMID 3907823 DOI: 10.1097/00002826-198512000-00003  0.323
1985 Bruno G, Ruggieri S, Chase TN, Bakker K, Tamminga CA. Caerulein treatment of Parkinson's disease. Clinical Neuropharmacology. 8: 266-70. PMID 3899353 DOI: 10.1097/00002826-198509000-00007  0.389
1985 Massari VJ, Shults CW, Park CH, Tizabi Y, Moody TW, Chronwall BM, Culver M, Chase TN. Deafferentation causes a loss of presynaptic bombesin receptors and supersensitivity of substance P receptors in the dorsal horn of the cat spinal cord. Brain Research. 343: 268-74. PMID 2413960 DOI: 10.1016/0006-8993(85)90744-9  0.303
1984 Foster NL, Chase TN, Mansi L, Brooks R, Fedio P, Patronas NJ, Di Chiro G. Cortical abnormalities in Alzheimer's disease. Annals of Neurology. 16: 649-54. PMID 6335378 DOI: 10.1002/Ana.410160605  0.308
1984 Foster NL, Newman RP, LeWitt PA, Gillespie MM, Larsen TA, Chase TN. Peripheral beta-adrenergic blockade treatment of parkinsonian tremor. Annals of Neurology. 16: 505-8. PMID 6149724 DOI: 10.1002/Ana.410160412  0.357
1984 Foster NL, Newman RP, LeWitt PA, Gillespie MM, Chase TN. Treatment of resting tremor by beta-adrenergic blockade. American Heart Journal. 108: 1173-7. PMID 6148881 DOI: 10.1016/0002-8703(84)90603-3  0.328
1984 Knight M, Tamminga CA, Steardo L, Beck ME, Barone P, Chase TN. Cholecystokinin-octapeptide fragments: binding to brain cholecystokinin receptors. European Journal of Pharmacology. 105: 49-55. PMID 6092115 DOI: 10.1016/0014-2999(84)90647-2  0.306
1983 Foster NL, Chase TN, Denaro A, Hare TA, Tamminga CA. THIP treatment of Huntington's disease. Neurology. 33: 637-9. PMID 6221200 DOI: 10.1212/Wnl.33.5.637  0.348
1983 Cohen SL, Knight M, Tamminga CA, Chase TN. Cholecystokinin-octapeptide effects on conditioned-avoidance behavior, stereotypy and catalepsy. European Journal of Pharmacology. 83: 213-22. PMID 6129145 DOI: 10.1016/0014-2999(82)90254-0  0.305
1980 Beasley BL, Nutt JG, Davenport RW, Chase TN. Treatment with Tryptophan of Levodopa-Associated Psychiatric Disturbances Archives of Neurology. 37: 155-156. PMID 7356421 DOI: 10.1001/Archneur.1980.00500520053008  0.303
1980 Tamminga CA, Chase TN. Bromocriptine and CF 25-397 in the treatment of tardive dyskinesia. Archives of Neurology. 37: 204-5. PMID 6102461 DOI: 10.1001/Archneur.1980.00500530042004  0.359
Show low-probability matches.